Register to receive a free U.S. Market Report Suite for Cardiac Surgery report synopsis and brochure Previously, minimally invasive procedures for replacing a heart valve have targeted patients considered too risky for open-heart surgery. Recently, the FDA has announced that younger and potentially more active patients can take that option as well. Medtronic and Edward Lifesciences both
FDA Approves TAVR Systems to Younger, Low-Risk Heart Patients
